Medin-Modifying Nanoliposomes for Vascular Dysfunction

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

There is no known treatment to reverse the deleterious effects of medin, a protein that accumulates with aging and causes vascular dysfunction, oxidative stress, and inflammation, contributing to cerebrovascular and aging-related degenerative diseases.

Innovation Solution

Medin-modifying nanoliposomes, composed of phospholipid, cholesterol, and glycosphingolipid, are used to alter medin's biologic properties, reducing its toxicity and inflammation, and are formulated with therapeutic cargoes to treat cerebrovascular and aging-related diseases.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If medin protein accumulates with aging, then vascular dysfunction and inflammation increase, but no effective treatment exists to reverse these effects

Engineering Contradiction:

Improvevascular functionVSAvoidmedin-induced toxicity and inflammation

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent uses nanoliposomes as intermediary carriers to deliver therapeutic agents (such as clusterin, antibodies, or other medin-binding molecules) to target medin protein. The nanoliposome structure comprises phospholipids, cholesterol, and glycosphingolipids, forming a biocompatible vehicle that can bind to medin and facilitate its clearance or neutralization, thereby reversing medin-induced vascular dysfunction without requiring direct administration of harsh therapeutic agents

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The invention employs composite nanoliposome formulations combining multiple lipid components (phospholipids, cholesterol, glycosphingolipids) with therapeutic cargo molecules. This composite structure enhances the stability, targeting capability, and therapeutic efficacy of the treatment while reducing off-target effects and inflammation associated with single-component therapies

Inventive Principle:

Principle #40Composite materials

2Reliability

If medin accumulates in blood vessels, then oxidative stress and endothelial dysfunction increase, but conventional treatments cannot effectively address these age-related changes

Engineering Contradiction:

Improveendothelial functionVSAvoidoxidative stress and vascular degeneration

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The nanoliposome formulation incorporates medin-binding molecules (such as clusterin or specific antibodies) that enable the system to automatically recognize and bind to medin protein in the vascular system. This self-targeting capability allows the therapeutic to selectively accumulate at sites of medin accumulation, facilitating localized treatment of endothelial dysfunction and oxidative stress without requiring external targeting mechanisms

Inventive Principle:

Principle #25Self-service

Solution Approach 2:

The patent utilizes the unique physicochemical parameters of nanoliposomes (size, surface charge, lipid composition) to optimize their interaction with medin protein and vascular endothelium. By adjusting lipid ratios, particle size, and surface modifications, the formulation achieves enhanced vascular permeability, prolonged circulation time, and improved binding affinity to medin, thereby effectively addressing oxidative stress and endothelial dysfunction

Inventive Principle:

Principle #35Parameter changes

Data Source

PatentUS12383500B2Nanoliposome compositions and methods of using the same

Publication Date: 2025.08.12 THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPT OF VETERANS AFFAIRS

AI summary

Disclosed herein are compositions comprising nanoliposomes useful for the treatment and prevention of cerebrovascular and aging-related degenerative diseases.